The test has insane accuracy precision.
A recent study unveils the potential of a blood test in detecting early-stage pancreatic cancers with remarkable accuracy, reaching up to 97%, as revealed by researchers.
The test relies on the identification of a specific genetic “signature” created by eight small RNA particles and eight larger DNA markers shed by pancreatic cancers, marking a significant advancement in early detection methods. Currently, pancreatic cancer is notoriously challenging to diagnose in its early stages due to its deep abdominal location and symptoms often mistaken for other ailments.
Dr. Ajay Goel, the senior researcher and chair of molecular diagnostics and experimental therapeutics at City of Hope Cancer Center, highlighted the severity of pancreatic cancer’s prognosis, emphasizing that most patients receive diagnoses only after the disease has metastasized. The survival rate drops drastically from 44% for early-stage diagnoses to a mere 3% if the cancer has already spread to other parts of the body.
A previous trial involving 95 patients from the U.S. and Japan showcased an impressive detection rate of 98%. The latest trial expanded significantly, encompassing 523 individuals with pancreatic cancer and 461 healthy participants from various countries, including Japan, the U.S., South Korea, and China.
Results from the trial demonstrated the blood test’s effectiveness across different populations, detecting pancreatic cancers at rates of 93% among U.S. participants, 91% among South Koreans, and 88% among the Chinese group. Moreover, when combined with an existing pancreatic cancer marker called CA 19-9, the test’s accuracy surged to 97% for detecting stage 1 and 2 cancers among U.S. participants.
Dr. Goel emphasized the superiority of their approach, particularly in identifying early-stage diseases, compared to the conventional CA19-9 measurement alone. However, researchers caution that further validation is necessary before the test can be implemented for widespread use.
The findings, presented at a meeting of the American Association for Cancer Research in San Diego, underscore the potential significance of this blood test in revolutionizing pancreatic cancer diagnosis and ultimately improving patient outcomes. As with all preliminary research findings, validation through peer-reviewed publication is essential before clinical application.
Discussion about this post